Delineating common molecular mechanisms in Alzheimer's and prion diseases

Trends in Biochemical Sciences

Volumn 31, Issue 8, 2006, Pages 465-472

  Barnham, Kevin J ^a,b   Cappai, Roberto ^a,b   Beyreuther, Konrad ^c   Masters, Colin L ^a,b   Hill, Andrew F ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; COPPER; PRION PROTEIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; BRAIN CORTEX; CREUTZFELDT JAKOB DISEASE; HUMAN; LIPID BILAYER; METAL BINDING; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATION REDUCTION REACTION; PATHOGENESIS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN MOTIF; PROTEIN PROCESSING; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; COPPER; HUMANS; OXIDATION-REDUCTION; PRION DISEASES; PRIONS; PROTEIN STRUCTURE, SECONDARY;

EID: 33746304427     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2006.06.006     Document Type: Review

References (89)

1. Prusiner S.B. Prions. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13363-13383
2. Thompson A.J., and Barrow C.J. Protein conformational misfolding and amyloid formation: characteristics of a new class of disorders that include Alzheimer's and Prion diseases. Curr. Med. Chem. 9 (2002) 1751-1762
3. Bush A.I. The metallobiology of Alzheimer's disease. Trends Neurosci. 26 (2003) 207-214
4. Barnham K.J., et al. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 3 (2004) 205-214
5. Brown D.R. Copper and prion disease. Brain Res. Bull. 55 (2001) 165-173
6. Brown D.R., et al. Prion protein-deficient cells show altered response to oxidative stress due to decreased SOD-1 activity. Exp. Neurol. 146 (1997) 104-112
7. Jones S., et al. Recombinant prion protein does not possess SOD-1 activity. Biochem. J. 392 (2005) 309-312
8. Kanski J., et al. Role of glycine-33 and methionine-35 in Alzheimer's amyloid β-peptide 1-42-associated oxidative stress and neurotoxicity. Biochim. Biophys. Acta 1586 (2002) 190-198
9. Ali F.E., et al. Methionine regulates copper/hydrogen peroxide oxidation products of Aβ. J. Pept. Sci. 11 (2005) 353-360
10. Curtain C.C., et al. Alzheimer's disease amyloid-β binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem. 276 (2001) 20466-20473
11. Varadarajan S., et al. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's Aβ(1-42) and Aβ(25-35). J. Am. Chem. Soc. 123 (2001) 5625-5631
12. Varadarajan S., et al. Methionine residue 35 is important in amyloid β-peptide-associated free radical oxidative stress. Brain Res. Bull. 50 (1999) 133-141
13. Palmblad M., et al. Oxidation of methionine 35 attenuates formation of amyloid β-peptide 1-40 oligomers. J. Biol. Chem. 277 (2002) 19506-19510
14. Barnham K.J., et al. Neurotoxic, redox-competent Alzheimer's β-amyloid is released from lipid membrane by methionine oxidation. J. Biol. Chem. 278 (2003) 42959-42965
15. Bitan G., et al. A molecular switch in amyloid assembly: Met35 and amyloid β-protein oligomerization. J. Am. Chem. Soc. 125 (2003) 15359-15365
16. Wadsworth J.D., et al. Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science 306 (2004) 1793-1796
17. Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. 24 (2001) 519-550
18. Russ W.P., and Engelman D.M. The GxxxG motif: a framework for transmembrane helix-helix association. J. Mol. Biol. 296 (2000) 911-919
19. Kleiger G., et al. GxxxG and AxxxA: common α-helical interaction motifs in proteins, particularly in extremophiles. Biochemistry 41 (2002) 5990-5997
20. Arispe N., et al. Giant multilevel cation channels formed by Alzheimer disease amyloid β-protein [AßP-(1-40)] in bilayer membranes. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 10573-10577
21. Tickler A.K., et al. Methylation of the imidazole side chains of the Alzheimer disease amyloid-β peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity. J. Biol. Chem. 280 (2005) 13355-13363
22. Demuro A., et al. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280 (2005) 17294-17300
23. Marchesi V.T. An alternative interpretation of the amyloid Aβ hypothesis with regard to the pathogenesis of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9093-9098
24. Jacobsen J.S., et al. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx. 2 (2005) 612-626
25. Lau T.L., et al. Magnetic resonance studies of β-amyloid peptides. Aust. J. Chem. 56 (2003) 349-356
26. Jarrett J.T., and Lansbury P.T.J. Seeding 'one-dimensional crystallization' of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?. Cell 73 (1993) 1055-1058
27. Curtain C.C., et al. Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-β peptide with membrane lipid. J. Biol. Chem. 278 (2003) 2977-2982
28. Bokvist M., et al. Two types of Alzheimer's β-amyloid (1-40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation. J. Mol. Biol. 335 (2004) 1039-1049
29. Hirakura Y., et al. Alzheimer amyloid Aβ1-42 channels: effects of solvent, pH, and Congo Red. J. Neurosci. Res. 57 (1999) 458-466
30. Lin H., et al. Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J. 15 (2001) 2433-2444
31. Kim S., et al. Transmembrane glycine zippers: physiological and pathological roles in membrane proteins. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 14278-14283
32. Xu Y., et al. Conformational transition of amyloid β-peptide. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 5403-5407
33. Hegde R.S., et al. A transmembrane from of the prion protein in neurodegenerative disease. Science 279 (1998) 827-834
34. Hegde R.S., et al. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 402 (1999) 822-826
35. Stewart R.S., et al. Neurodegenerative illness in transgenic mice expressing a transmembrane form of the prion protein. J. Neurosci. 25 (2005) 3469-3477
36. Parkin E.T., et al. Dual mechanisms for shedding of the cellular prion protein. J. Biol. Chem. 279 (2004) 11170-11178
37. Vincent B., et al. The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. J. Biol. Chem. 276 (2001) 37743-37746
38. Cisse M.A., et al. The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity. J. Biol. Chem. 280 (2005) 40624-40631
39. Laffont-Proust I., et al. The N-terminal cleavage of cellular prion protein in the human brain. FEBS Lett. 579 (2005) 6333-6337
40. Chen S.G., et al. Truncated forms of the human prion protein in normal brain and in prion diseases. J. Biol. Chem. 270 (1995) 19173-19180
41. Watt N.T., et al. Reactive oxygen species-mediated β-cleavage of the prion protein in the cellular response to oxidative stress. J. Biol. Chem. 280 (2005) 35914-35921
42. Brown D.R., et al. The cellular prion protein binds copper in vivo. Nature 390 (1997) 684-687
43. White A.R., et al. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res. 842 (1999) 439-444
44. White A.R., et al. Prion protein-deficient neurons reveal lower glutathione reductase activity and increased susceptibility to hydrogen peroxide toxicity. Am. J. Pathol. 155 (1999) 1723-1730
45. Mattson M.P., et al. Secreted form of amyloid precursor protein enhances basal glucose and glutamate transport and protects against oxidative impairment of glucose and glutamate transport in synaptosomes by a cyclic GMP-mediated mechanism. J. Neurochem. 73 (1999) 532-537
46. Lawson V.A., et al. N-terminal truncation of prion protein affects both formation and conformation of abnormal protease-resistant prion protein generated in vitro. J. Biol. Chem. 276 (2001) 35265-35271
47. Salmona M., et al. Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126. Biochem. J. 342 (1999) 207-214
48. Brown D.R., et al. Cellular effects of a neurotoxic prion protein peptide are related to its β-sheet content. Neurosci. Res. Commun. 23 (1998) 119-128
49. Lambert M.P., et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6448-6453
50. Vassallo N., and Herms J. Cellular prion protein function in copper homeostasis and redox signalling at the synapse. J. Neurochem. 86 (2003) 538-544
51. Maynard C.J., et al. Overexpression of Alzheimer's disease amyloid-β opposes the age-dependent elevations of brain copper and iron. J. Biol. Chem. 277 (2002) 44670-44676
52. C) expression and metabolism in neuronal cells. FEBS Lett. 579 (2005) 741-744
53. Atwood C.S., et al. Amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β. Brain Res. Brain Res. Rev. 43 (2003) 1-16
54. Huang X., et al. Cu(II) potentiation of alzheimer Aβ neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 274 (1999) 37111-37116
55. Tickler A.K., et al. Amyloid-β as a 'difficult sequence' in solid phase peptide synthesis. Protein Pept. Lett. 11 (2004) 377-384
56. Antzutkin O.N. Amyloidosis of Alzheimer's Aβ peptides: solid-state nuclear magnetic resonance, electron paramagnetic resonance, transmission electron microscopy, scanning transmission electron microscopy and atomic force microscopy studies. Magn. Reson. Chem. 42 (2004) 231-246
57. Syme C.D., et al. Copper binding to the amyloid-β (Aβ) peptide associated with Alzheimer's disease: folding, coordination geometry, pH dependence, stoichiometry, and affinity of Aβ-(1-28): insights from a range of complementary spectroscopic techniques. J. Biol. Chem. 279 (2004) 18169-18177
58. 2+ binding site in amyloid-β. Biochemistry 44 (2005) 5478-5487
59. 2+ in a mononuclear metal ion binding site. J. Am. Chem. Soc. 126 (2004) 13534-13538
60. Zirah S., et al. Structural changes of region 1-16 of the Alzheimer disease amyloid β-peptide upon zinc binding and in vitro aging. J. Biol. Chem. 281 (2006) 2151-2161
61. Lee J.Y., et al. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 7705-7710
62. Huang X., et al. Zinc-induced Alzheimer's Aβ1-40 aggregation is mediated by conformational factors. J. Biol. Chem. 272 (1997) 26464-26470
63. Atwood C.S., et al. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 273 (1998) 12817-12826
64. Terry R.D. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J. Neuropathol. Exp. Neurol. 55 (1996) 1023-1025
65. Burns C.S., et al. Molecular features of the copper binding sites in the octarepeat domain of the prion protein 301. Biochemistry 41 (2002) 3991-4001
66. Burns C.S., et al. Copper coordination in the full-length, recombinant prion protein. Biochemistry 42 (2003) 6794-6803
67. Jackson G.S., et al. Location and properties of metal-binding sites on the human prion protein. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 8531-8535
68. Jobling M.F., et al. Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126. Biochemistry 40 (2001) 8073-8084
69. Gaggelli E., et al. Interaction of the human prion PrP(106-126) sequence with copper(II), manganese(II), and zinc(II): NMR and EPR studies. J. Am. Chem. Soc. 127 (2005) 996-1006
70. Sc protease resistance and conversion-inducing activity. J. Biol. Chem. 279 (2004) 40788-40794
71. res. FASEB J. 19 (2005) 783-785
72. Shiraishi N., et al. Fragmentation and dimerization of copper-loaded prion protein by copper-catalysed oxidation. Biochem. J. 387 (2005) 247-255
73. Martins R.N., et al. Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J. Neurochem. 46 (1986) 1042-1045
74. res propagation as an early primary pathogenic event in prion disease. Brain Res. Bull. 68 (2006) 346-354
75. Behl C., et al. Hydrogen peroxide mediates amyloid β protein toxicity. Cell 77 (1994) 817-827
76. McLean C.A., et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 (1999) 860-866
77. Naslund J., et al. Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 8378-8382
78. Kuo Y.M., et al. Comparative analysis of amyloid-β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 276 (2001) 12991-12998
79. Barnham K.J., et al. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease β-amyloid. FASEB J. 18 (2004) 1427-1429
80. Paramithiotis E., et al. A prion protein epitope selective for the pathologically misfolded conformation. Nat. Med. 9 (2003) 893-899
81. Bocharova O.V., et al. Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils. Biochemistry 44 (2005) 6776-6787
82. Watt N.T., and Hooper N.M. Reactive oxygen species (ROS)-mediated β-cleavage of the prion protein in the mechanism of the cellular response to oxidative stress. Biochem. Soc. Trans. 33 (2005) 1123-1125
83. Breydo L., et al. Methionine oxidation interferes with conversion of the prion protein into the fibrillar proteinase K-resistant conformation. Biochemistry 44 (2005) 15534-15543
84. Cherny R.A., et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30 (2001) 665-676
85. Ritchie C.W., et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60 (2003) 1685-1691
86. Sigurdsson E.M., et al. Copper chelation delays the onset of prion disease. J. Biol. Chem. 278 (2003) 46199-46202
87. Tagliavini F., et al. A 7-kDa prion protein (PrP) fragment, an integral component of the PrP region required for infectivity, is the major amyloid protein in Gerstmann-Straussler-Scheinker disease A117V. J. Biol. Chem. 276 (2001) 6009-6015
88. Grziwa B., et al. The transmembrane domain of the amyloid precursor protein in microsomal membranes is on both sides shorter than predicted. J. Biol. Chem. 278 (2003) 6803-6808
89. Riek R., et al. NMR structure of the mouse prion protein domain PrP (121-231). Nature 382 (1996) 180-182